Glenmark Pharmaceuticals Limited — Q2 FY26
Glenmark's Q2 FY26 consolidated revenue surged 76% YoY to INR 6,047 crore, driven by the ISB 2001 out-licensing income.
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q1 FY26
Europe to return to double-digit growth from Q2 FY26
Management anticipates Europe region returning to double-digit growth from Q2 FY26 and expects double-digit growth for full year FY26.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1